Obstetrics and Gynecology· Topic 11.4 Vulvovaginal disorders and genital tract infection· 11.4.20

Mycoplasma genitalium infection

Mycoplasma genitalium is an emerging sexually transmitted pathogen and a leading cause of nongonococcal, nonchlamydial urethritis in men and of cervicitis and pelvic inflammatory disease in women. Diagnosis requires nucleic acid amplification testing, and treatment is resistance-guided, with doxycycline lead-in therapy followed by extended azithromycin or moxifloxacin because macrolide resistance is increasingly common.

11 min read8 practice questions8 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    Emerging sexually transmitted pathogen: Mycoplasma genitalium is a small, cell-wall-deficient bacterium recognized as an emerging cause of nongonococcal urethritis in men and cervicitis/pelvic inflammatory disease (PID) in women.

  • Epidemiology

    Sexually transmitted, person-to-person spread: M.

  • Risk factors

    Sexual contact with an infected partner: the direct mechanism of acquisition, as with other sexually transmitted pathogens.

  • Pathophysiology

    Mucosal epithelial adherence: M. genitalium adheres to and colonizes the urethral, cervical, and endometrial mucosal epithelium, initiating local inflammation.

  • Clinical features

    Urethritis in men: dysuria and mucopurulent or clear urethral discharge; M.

  • Differential diagnosis

    Neisseria gonorrhoeae urethritis/cervicitis: typically more purulent discharge, and Gram stain shows intracellular gram-negative diplococci; distinguished by NAAT or culture.

  • Diagnosis

    Confirmed by nucleic acid amplification testing; there is no routine screening recommendation: the diagnosis is established by a U.S.

  • Management

    Start with doxycycline lead-in therapy: doxycycline 100 mg PO twice daily for 7 days is given first for confirmed or strongly suspected M.

  • Complications

    Pelvic inflammatory disease: ascending infection can cause endometritis and salpingitis with lasting reproductive consequences.

  • Prognosis

    Good with resistance-guided treatment: appropriately sequenced doxycycline lead-in followed by susceptibility-directed azithromycin or moxifloxacin achieves cure in most patients.

  • Prevention

    Consistent barrier contraception: condom use reduces the risk of acquisition and transmission, as with other sexually transmitted infections.

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.